Ironwood Pharmaceuticals | IRWD - Current Assets


Ironwood Pharmaceuticals reported $332.29M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Akebia Therapeutics USD 243.48M 9.47M Mar/2026
Almirall EUR 713.98M 69K Dec/2025
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Amarin USD 626.02M 23.87M Mar/2026
Ardelyx USD 381.87M 447K Mar/2026
Astellas Pharma JPY 1.42T 19.35B Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
Charles River Laboratories USD 1.49B 41.76M Mar/2026
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Ironwood Pharmaceuticals USD 332.29M 58.11M Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
MacroGenics USD 182.52M 37.42M Mar/2026
Moderna USD 5.77B 774M Mar/2026
Myriad Genetics USD 312.8M 19.8M Mar/2026
Pacira USD 514.96M 33.01M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Takeda JPY 3.09T 25.94B Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025